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Calcium channel blockers protect transplant patients from cyclospo-
rine-induced daily renal hypoperfusion. Renal toxicity, possibly due to
vasoconstriction and vascular injury, is the most relevant side-effect of
chronic cyclosporine (CsA) therapy given to prevent graft rejection. In
kidney transplant recipients each oral dose of CsA is invariably
followed by a transient reduction in renal plasma flow (RPF) and
glomerular filtration rate (GFR) that results from a form of acute
reversible hypoperfusion. We sought to determine whether the Ca2
channel blocker, lacidipine, prevented CsA-associated renal hypoper-
fusion in these patients. Parallel studies on CsA pharmacokinetics,
renal function parameters (GFR and RPF), as inulin and p-aminohip-
purate (PAH) clearances, respectively, and urinary excretion of the
vasoconstrictor endothelin in 10 consecutive renal transplant patients
given CsA as a part of their immunosuppressive therapy were per-
formed. Patients were studied at different time intervals after CsA
alone, CsA and lacidipine (4 mg/day), and again seven days after
lacidipine withdrawal. In all patients basal RPF and GFR declined on
average 51% (139.3 20.7 ml/min/1.73 m2) and 50% (32.5 5.8
ml/min/l .73 m2), respectively, two to four hours after maximum blood
CsA concentration was reached. As blood levels of CsA returned to
trough, both parameters progressively increased to baseline. Lacidipine
administration completely prevented the fall in RPF (pre-CsA: 277.1
23.6; 6 hr post-CsA: 304.5 31.1 ml/min/l.73 m2) and GFR (pre-CsA:
66.6 8.1; 6 hr post-CsA: 70.1 9.8 mI/mm/i .73 m2). When lacidipine
treatment was discontinued the abnormal RPF and GFR response to
CsA administration was again observed. Lacidipine administration did
not prevent the increase in urinary excretion of endothelin which was
observed after CsA alone, and was temporarily related to the decline in
GFR. Daily renal hypoperfusion induced by CsA in renal transplant
patients is completely prevented by the administration of the calcium
channel blocker, lacidipine, which did not impair the endothelin syn-
thetic pathway.
The use of CsA to prevent graft rejection is associated with
major nephrotoxicity, which is likely a consequence of the toxic
effect of CsA on vascular endothelium as consistently docu-
mented in experimental animals and humans [1—3]. We have
recently found that in humans with a kidney transplant, each
administration of CsA was invariably associated with a reduc-
tion in GFR and RPF which was transient and negatively
correlated with CsA Cmax [4]. The rapid reversibility of this
phenomenon suggested an acute vasoconstriction, a phenome-
non already observed in experimental animals exposed to CsA
[5]. It has been speculated that the repeated daily episodes of
acute renal hypoperfusion explain structural alterations of
pre-glomerular vessels and glomerular obsolescence well doc-
umented in patients who were treated for two years or more on
chronic CsA [6, 7].
Starting from recent data that Ca2 channel blockers may
attenuate CsA-associated hypertension [8, 91, the present study
was designed to evaluate whether the Ca2 channel blockers
prevented CsA-associated renal hypoperfusion in renal trans-
plant patients. To this purpose we did parallel studies on renal
function and CsA pharmacokinetics in 10 consecutive renal
transplant patients given CsA as a part of their immunosuppres-
sive regimen. Renal clearance studies were done before and
after a week of treatment with a Ca2 channel blocker, and
were repeated a week after withdrawal of the Ca2 channel
blocker. Since in the previous study CsA-induced renal hypo-
perfusion was associated with an increased urinary excretion of
endothelin [4], a potent endogenous vasoconstrictor [10], we
also addressed whether the use of Ca2 channel blockers
prevents the increase in urinary endothelin.
Methods
Patient population
Ten outpatients (2 female, 8 male) regularly followed at the
Division of Nephrology, Ospedali Riuniti Bergamo, who from
six months received renal transplantation were studied. The
study protocol was described in detail to all patients before
admission, and informed consent to perform the study was
obtained in each instance. Patients were on chronic immuno-
suppression with triple therapy which included CsA, pred-
nisone, and azathioprine [4]. The average age of the patients
was 42 8 years (range 33 to 59). All patients had stable renal
function as documented by changes in creatinine clearance less
than 30% over the last three months, and no clinical proteinuria
(<0.5 g124 hr).
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Study protocol
Each patient entered the study after one week of washout of
the previous antihypertensive therapy.
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The effect of the Ca2 channel blocker, lacidipine [(E)-4-(2-
(3-( 1, 1-dimethyllethoxy)-3-oxo- l-pro-phenyl-1 ,4-dihydro-2,6-di-
methyl-3,5-pyridinedicarboxylic acid] (Glaxo Ltd, Verona, It-
aly) [11], on renal function, CsA pharmacokinetics and urinary
endothelin excretion was evaluated using a sequential study
protocol. A first evaluation was done before lacidipine treat-
ment. Starting right after the basal evaluation patients received
4 mg lacidipine once daily in the morning for seven days, at the
end of which the study was repeated. A third clearance study
was performed seven days after lacidipine withdrawal. These
three study periods are referred to as baseline, lacidipine, and
lacidipine withdrawal, respectively. The last dose of lacidipine
was given 10 minutes before CsA administration. In each of the
three study periods samples were taken before and at regular
intervals after a single oral dose of 3.5 mg/kg CsA. On the
morning of the study, blood was drawn for estimation of serum
creatinine concentration and hematocrit values. Then each
patient underwent sequential renal clearance studies [3]. In
brief, clearances of inulin and para-aminohippurate (PAH) were
performed under a steady state of diuresis induced by oral
water loading followed by continuous intravenous infusion of
saline solution at the rate of 250 mi/hr. Thereafter saline
infusion rate was adjusted to maintain urine flow relatively
constant throughout the study. A priming dose, followed by a
constant infusion of 10% inulin and 20% PAH was adminis-
tered. The sustained dose of inulin and PAH was started to
maintain constant plasma concentration of —0.15 and 0.015
mg/mi, respectively. After a 60-minute equilibration period and
a two-hour baseline clearance period, CsA, or lacidipine and
CsA were given orally and then six carefully timed urine
collections (2 hr each) were made. Urine was collected by
spontaneous voiding and blood samples were drawn at the
beginning and at the end of each clearance period. GFR was
calculated as the urinary clearance of inulin and corrected for
body surface area for each clearance period. RPF was calcu-
lated as the urinary clearance of PAH. Renal vascular resis-
tance (RVR) was estimated by dividing the mean arterial
pressure (MAP) by renal blood flow, where the latter has been
computed from RPF and the fractional hematocrit. Before, 30,
60 minutes after CsA administration and at hourly intervals
thereafter for 12 hours blood samples were collected from the
antecubital vein for measurement of CsA levels in the blood. In
the same patients the excretion rate of endothelin was also
measured over two six-hour interval periods after CsA admin-
istration. Endothelin excretion was estimated on urine samples
collected between 2:00 and 8:00 a.m. before the baseline
clearance study.
Analytical procedures
To calculate GFR, the concentration of inulin in urine and
plasma was measured by the thiourea-resorcinol method [12].
The method of Smith et a! [13] was used to measure PAH
concentrations. Preliminary experiments in normal rats have
shown that lacidipine did not alter renal PAH extraction (N.
Perico et al, personal communication).
Blood CsA concentration was determined by high perfor-
mance liquid chromatography (HPLC), as previously described
[4, 14]. Results were expressed as ng/ml. The blood concentra-
tion-time profile of CsA was recorded for all patients together
with trough level (blood concentration before the next admin-
Table 1. Systemic and renal function parameters before, during, and
after lacidipine in kidney transplant recipients given CsA
Lacidipine
Baseline Lacidipine withdrawal
SBP mm Hg 142.4 6.9 124.8 8.5a 135.9 8.0
DBP mm Hg 93.1 6.1 79.4 6.4a 88.4 8.9
Serum creatinine 111.4 19.7 107.8 20.8 112.3 19.1
Iinol/liter
Urine output ml/14 hr 1401 408 2050 572 1339 397
Abbreviations are: SBP, systolic blood pressure; DBP, diastolic
blood pressure.
a P < 0.01 vs. Baselme and lacidipine withdrawal
istration), the maximum concentration (Cmax), and the time of
maximum observed concentration (Tmax) of blood CsA. The
area under the blood concentration curve from time equals zero
to the last sampling point (12 hr) (AUC 0—*12) was calculated by
trapezoidal rule.
Urinary samples underwent extraction before radioimmuno-
assay (RIA) for endothelin [15]. Briefly, urines were spiked with
1,000 cpm '251-endothelin (2,000 Ci/mmol, Amersham, Buckin-
gamshire, UK), as a tracer for the extraction procedure. Sam-
ples were added with 100 p1 of acetonitrile:water (1:2, vol/vol)
and centrifuged at 1,700 x g for 10 minutes before the extrac-
tion. Samples were then applied to a C18-Sep Pak disposable
column (Millipore, Water Associated, Mildford, Massachu-
setts, USA), previously activated with different methanol:water
solutions containing increasing amount of solvent. The column
was then lyophylized and resuspended in RIA buffer immedi-
ately before the RIA procedure. Extraction recovery ranged 70
to 80%. RIA was performed using a commercially available
antibody (Peninsula Laboratories, Inc., Belmont, Osaka, Ja-
pan). Inter- and intra-assay variability averaged 10% and 14%,
respectively.
Statistical analysis
All data are reported as means SD. Results were analyzed
by Repeated Measure Analysis of Variance using the Procedure
GLM of SAS/STAT software, version 6. Multiple comparisons
were performed using the Statement Contrast [16]. Statistical
significance was defined as P <0.05.
Results
Mean systolic and diastolic blood pressure recorded during
the clearance studies are reported in Table 1. Systolic and
diastolic blood pressure were both significantly lower at the end
of the lacidipine treatment than during basal evaluation. After
lacidipine withdrawal both systolic and diastolic blood pressure
returned to pre-Ca2 antagonist values.
No significant difference was observed in mean serum creat-
mine levels during the three clearance studies (Table I). Mean
urine output was significantly higher during lacidipine than
baseline evaluation, and returned to pre-treatment values after
discontinuing the drug (Table 1). Actually, lacidipine adminis-
tration was consistently associated with a progressive increase
in urine output that peaked four hours after dosing. A progres-
sive reduction toward pre-treatment values was observed there-
after with complete recovery 8 to 10 hours after lacidipine
administration.
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Fig. 1. Mean values of glomerular filtration rate (boxes) and area
under the ,urve (circles) values for blood cyclosporine over a 12 hour
period in re,jal transplant recipients before (baseline), during lacidipine
treatment (lacidipine), and 7 days after lacidipine withdrawal (laci-
dipine withdrawal). Values are mean SD. * P< 0.05 vs. baseline and
lacidipine withdrawal.
Mean values of GFR over a 12 hour period in renal transplant
recipients during the three clearance studies are given in Figure
1. As determined by inulin clearance, basal GFR averaged 53.6
6.0 mI/mm/i .73 m2. By the end of lacidipine treatment in all
patients mean GFR showed a tendency to increase, averaging
66.8 10.1 mllmin/1.73 m2, a value significantly different (P <
0.05) compared to basal evaluation. When lacidipine treatment
was withdrawn GFR declined again to an average of 53.6 5.3
ml/min/1.73 m2. Similar changes have been observed for mean
RPF, which values averaged 224.9 22.2, 299.4 29.5, and
226.9 20.3 mI/mm/i .73 m2 before, after lacidipine treatment,
and a week after lacidipine discontinuation, respectively. Fig-
ure 2 shows sequential profiles of GFR and RPF in a represen-
tative renal transplant patient during the three clearance stud-
ies. As previously documented [4], CsA administration resulted
in a progressive decline in GFR, reaching the nadir six hours
after dosing. Thereafter GFR progressively increased to the
basal values. Lacidipine almost completely prevented the fall in
GFR. Withdrawal of the Ca2 channel blocker was again
associated with a reversible deterioration of renal function
when a single dose of CsA was administered. Similar profiles
were documented for RPF. Thus, while CsA transiently re-
duced renal perfusion, pretreatment with lacidipine prevented
the phenomenon which was observed again by discontinuing
the Ca2 channel blocker.
As shown in Table 2, GFR declined on average 50% six hours
after CsA administration as compared to basal values (P <
0.01). The fall in GFR was completely prevented by pretreating
patients with lacidipine. When lacidipine was discontinued
GFR decreased again after CsA as in the basal study. A parallel
reduction of RPF was found when patients were given CsA
alone, with an average fall of 51%. When RPF evaluation was
performed in the presence of lacidipine no significant changes in
RPF were recorded after CsA as compared to baseline values.
Similarly, lacidipine consistently prevented the increase in
RVR observed when patients were given CsA alone (Table 2).
Filtration fraction remained unchanged during the three studies.
Table 3 shows trough concentration, area under the curve,
peak blood concentrations and time to peak after CsA admin-
istration with or without lacidipine. Mean trough CsA levels in
patients receiving CsA were comparable with and without
lacidipine (Table 3). Calculated AUC values during the study
with CsA alone were numerically lower than during the corn-
—. bined administration of CsA and lacidipine (Table 3), although
the difference did not reach statistical significance. After dis-
continuation of lacidipine AUC values returned to baseline.
Similarly, Cmax showed a tendency to increase with lacidipine
< treatment compared to baseline values, but the difference was
not statistically significant. Withdrawal of lacidipine was asso-
ciated with a decline of Cmax values toward baseline. Tmax was
comparable for all the three study periods (on average 2'/2 hr).
Urinary excretion of endothelin is given in Figure 3, Values
were significantly higher in the urine collected zero to six hours
after CsA (18.19 7.73 pg/mg creatinine) than in the six hours
preceding the treatment (6.31 2.76 pg/mg creatinine). In the
following six hour collection endothelin levels returned to
pre-CsA values (9.64 3.78 pg/mg creatinine). Lacidipine
treatment did not influence urinary endothelin excretion, as
documented by comparably increased excretion values of the
peptide in patients while on CsA alone compared to CsA and
lacidipine (Fig. 3) studied at the same time interval after CsA.
Discussion
The present results indicate that in renal transplant patients
participating in the study, a single oral dose of 3.5 mg/kg of CsA
was followed by a 50% reduction in GFR and RPF, which
consistently occurred two to four hours after Cmax blood
concentration of CsA was reached. These findings likely reflect
a sudden increase in the afferent arteriolar tone [6] and probably
represent the human counterpart of what has been observed in
experimental animals [17]. In the rat CsA has been reported to
decrease glomerular plasma flow by reducing the caliber of
afferent arteriole [17]. If this occurred in humans peripheral
vasodilators may possibly antagonize CsA-associated renal
hypoperfusion. Ca2 channel blockers appear ideal candidates
because of their predominant effect at preglomerular level [18].
Thus, videomicroscopic measurements of renal microvascular
dimension in rat juxtamedullary nephrons showed that vera-
pamil and diltiazem selectively antagonized the effect of angio-
tensin II on afferent arteriolar diameter while they did not
influence efferent arteriole tone [18]. These findings offered an
elegant explanation to previous data on the protective effect of
Ca2 antagonists on renal function in several experimental
models of hemodynamic renal impairment [19—21]. Even more
importantly, on the same line was the recent evidence that
nifedipine ameliorated CsA-associated hypertension and had a
favorable long-term effect on renal function in renal transplant
patients on chronic CsA [8, 9].
We therefore sought to evaluate whether Ca2 channel
blockers prevented CsA-associated renal hypoperfusion. The
data showed that lacidipine completely prevented the fall in
GFR which invariably occurs two to four hours after blood CsA
Cmax. These results are in harmony with the above-mentioned
evidence that Ca2 channel blockers preferentially reduce
afferent arteriole tone [18, 19].
The beneficial effect of lacidipine on CsA-induced renal
hypoperfusion was not due to changes in pharmacokinetics.
Actually, in our patients lacidipine administration was associ-
ated with a numerical increase of CsA AUC, which returned to
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Fig. 2. Simultaneous monitoring of blood
cyclosporine (GsA) concentration and
glomerular filtration rate (GFR) in a
representative patient before (A, baseline),
during lacidipine treatment (B, lacidipine),
and 7 days after lacidipine withdrawal (C,
iacidipine withdrawal).
Table 2. Blood CsA levels, GFR, RPF, and RVR values in all patients before, during lacidipine, or after lacidipine withdrawal
Basal
2 6 12
hours after CsA
Baseline
Blood CsA level ng/mi 97 43 782 481 337 134 136 35
GFR mi/minI] .73 in2 63.7 7.4 63.6 7.3 32.5 5.8" 64.2 6.0
RPF mI/mini] .73 n2 271.0 23.4 270.0 25.8 139.3 20.7" 272.5 22.2
RVR mm Hg/mI/mini] .73 m2 0.231 0.020 0.222 0.023 0.430 0.069" 0.227 0.020
Lacidipine
Blood CsA level ngml
GFR mi/mini] .73 m
103 46
66.6 8.1
919 459
70.8 10.4
327 112
70.1 9.8
143 53
70.7 9.8
RPF mi/mini] .73 m2 277.1 23.6 303.8 30.2 304.5 31.1 302.7 31.0
RVR mm Hg/mI/mini] .73 m2 0.209 0.025 0.165 0.024 0.168 0.024 0.183 0.021
Lacidipine withdrawal
Blood CsA level ng/mi 100 41 750 484 305 64 138 40
GFR mI/mini] .73 in2 63.2 7.6 63.0 7.5 32.6 3.9" 63.5 6.8
RPF mi/minij.73 m2 272.5 25.2 271.1 23.7 142.7 183b 273.6 25.9
RVR mm Hg/mi/mini] .73 m2 0.221 0.029 0.210 0.028 0.387 0.064" 0.216 0.031
Values are mean SD. Abbreviations are: CsA, cyclosporine; GFR, glomerular filtration rate; RPF, renal plasma flow; RVR, renal vascular
resistance.
a p < 0.01 vs. Basal, 6 hr, and 12 hr
b P < 0.01 vs. Basal, 2 hr, and 12 hr
Table 3. CsA pharmacokinetic parameters in renal transplant
patients before, during and after withdrawal of lacidipine
Lacidipine
Baseline Lacidipine withdrawal
C trough ng/ml 97 43 103 46 100 41
AUC(0— 12)ngimlhr 4015 1225 4596 1439 4025 1181
Cmax ng/ml 899 392 1110 367 893 343
Tmax hr 2.8 1.6 2.5 0.9 2.6 0.7
Abbreviations are: C trough, CsA trough concentration; AUC, area
under the curve; Cmax, peak CsA blood concentration; Tmax, time to
peak of CsA blood concentration. Values are mean SD.
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Fig. 3. Urinary endothelin (ET) excretion in renal transplant recipients
after CsA alone (baseline), during CsA and lacidipine treatment (laci-
dipine), and 7 days after lacidipine withdrawal (iacidipine withdrawal).
Symbols are: (D) post-CsA 0—6 hr; () post-CsA 6—12 hr. Basal values
for urinary ET excretion in samples collected before CsA administra-
tion were: 6.31 2.76 pg/mg creatinine. Values are mean si. * U
0.01 vs. post-CsA (6 to 12 hr).
baseline after lacidipine withdrawal. This can easily be ex-
plained by the fact that in the liver Ca2 channel blocking
agents inhibit cytochrome P-450 enzyme system [22, 23] thus
reducing the metabolism of CsA [24, 25].
While animal data have very convincingly documented that
CsA increases afferent arteriolar tone [17], the mechanism(s)
responsible for such an effect is still matter of speculation.
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Recent data have documented that endothelial cells in culture
exposed to CsA, in the supernatant release the potent endothe-
hal-derived endogenous vasoconstrictor endothelin [261. Since
in rats, endothelin increases glomerular afferent arteriolar tone
and reduces single nephron GFR and ultrafiltration coefficient
[271, one can speculate that endothelin participates in CsA-
associated vasoconstriction. That excessive local endothelin
release was the biochemical basis of CsA vasoconstriction, at
least in the rat, is consistent with data of increased endothelin
urinary excretion in animals given CsA [28] as well as with
findings of a specific increase in endothelin receptors in the
kidney, but not in the liver [29].
Our previous study has also documented that urinary excre-
tion of endothehin was increased in transplant patients on CsA
with a pattern that paralleled CsA concentration in the blood,
and was temporarily related to the decline in GFR [41. The
findings of the present study confirm the increase of endothelin
excretion rate few hours after CsA has reached its peak blood
concentration. The administration of lacidipine did not prevent
the increase in urinary endothelin despite completely prevent-
ing renal hypoperfusion. Within the limit of the assumption that
endothelin mediates CsA-induced renal vasoconstriction, the
present data indicate that Ca2 channel blockers did not influ-
ence the effect of CsA on endothelin synthesis, but eliminate its
functional consequence. This interpretation is consistent with
recent evidence that vascular smooth muscle cell contraction
induced by endothelin is dependent from activation of L-type
Ca2 channels [30, 31], and that nicardipine reduced afferent
arteriolar tone by inducing a concentration-dependent shift in
the endothelin- 1 concentration-response curve [32]. An alterna-
tive interpretation of these findings is that increased renal [33]
endothelin synthesis is not the main cause of CsA-associated
renal hypoperfusion, but other mediators [3] play a relevant
role. This latter interpretation, however, does not fit with
previous experimental findings that in isolated perfused rat
kidney [34], as well as in in vivo experiments [27], a specific
anti-endothelin antibody completely and consistently prevented
the increase in arteriolar resistance and the reduction in single
nephron GFR associated with CsA.
Renal biopsies performed in cardiac transplant patients after
two years of daily administration of CsA (5.0 2.2 mg/kg/day)
showed global or segmental sclerosis in 42% of glomeruli which
were smaller than normal as indicated by tridimensional mor-
phometrical analysis [7]. Evidence is available that CsA ne-
phropathy may progress with time so that the cumulative
incidence of end-stage renal failure approximates 10% in the
first decade after transplantation and can be expected to rise
substantially in the following decades [2]. If one assumes that
CsA-induced renal ischemia may eventually contribute—at
least in part—to the loss of glomerular filtering units, Ca2
channel blockers, by eliminating recurrent hypoperfusion, may
help reduce the long-term consequences of such phenomenon.
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